Azafaros aims at developing new therapeutic agents for the treatment of rare metabolic disorders.
Azafaros has raised $146.7M in total funding. The most recent round was Series B. The last funding was announced in May 2025.
Azafaros's investors include Schroders Capital, Jeito Capital, BioGeneration Ventures, Pictet Alternative Advisors, Forbion Capital Partners.
Azafaros is headquartered in Leiden, The Netherlands.
Azafaros aims at developing new therapeutic agents for the treatment of rare metabolic disorders.
Azafaros is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Azafaros — Funding & Investors." VCBacked, May 13, 2025, https://www.vcbacked.co/company/azafaros. Accessed September 15, 2026.
VCBacked. (2025). Azafaros — Funding & Investors. Retrieved September 15, 2026, from https://www.vcbacked.co/company/azafaros
{{cite web |title=Azafaros — Funding & Investors |url=https://www.vcbacked.co/company/azafaros |website=VCBacked |access-date=September 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated